Evidence map›Paper›PMID 38850461›Full record

ArticleArchives of dermatological research2024

Patient-reported burden in adults with atopic dermatitis: an international qualitative study.

Andreas Wollenberg, Melinda Gooderham, Norito Katoh, Valeria Aoki, Andrew E Pink, Yousef Binamer, Jonathan I Silverberg

Abstract readMulticenter Study
In one paragraph

Article in Archives of dermatological research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Efficacy of up to 4 years of tralokinumab in adults with moderate-to-severe atopic dermatitis.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026
    Trial
  4. Improvement and maintenance of clinical outcome assessments in atopic dermatitis with amlitelimab.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025
    Trial
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Andreas WollenbergDepartment of Dermatology and Allergy, Ludwig-Maximilian University of Munich, Munich, Germany. wollenberg@lrz.uni-muenchen.de.ORCID http://orcid.org/0000-0003-0177-8722
Melinda GooderhamDepartment of Dermatology, Queen's University, Ontario, Canada.ORCID http://orcid.org/0000-0001-8926-0113
Norito KatohDepartment of Dermatology, Kyoto Prefectural University of Medicine, Kyoto, Japan.ORCID http://orcid.org/0000-0002-3498-2482
Valeria AokiDepartment of Dermatology, University of São Paulo School of Medicine, São Paulo, Brazil.ORCID http://orcid.org/0000-0003-4256-4413
Andrew E PinkSt. John's Institute of Dermatology, Guy's & St. Thomas' NHS Foundation Trust, London, UK.ORCID http://orcid.org/0000-0001-5151-5539
Yousef BinamerDepartment of Dermatology, Alfaisal University, Riyadh, Saudi Arabia.ORCID http://orcid.org/0000-0003-0948-7102
Jonathan I SilverbergSchool of Medicine and Health Sciences, George Washington University, Washington, DC, USA.ORCID http://orcid.org/0000-0003-3686-7805

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The objective was to study a large, international, ethnically diverse population of patients with atopic dermatitis (AD) to support the creation of patient-centric recommendations for AD management. Qualitative data were generated from 45-min, 1:1 telephone interviews conducted across 15 countries in each patient's native language. Interviews explored the impact of AD on patients' lives, patients' most important symptoms, treatment expectations, and treatment decision-making. Participants were also questioned on their current knowledge of AD scoring systems and what was most important to include in these tools. In total, 88 adult patients (≥ 18 years old) receiving treatment for AD were recruited through a market research database, clinician referrals, and local advertising. All patients were screened to ensure a balanced and diverse sample in terms of age, gender, educational level, employment status, geographic location, and AD severity. Patients involved in market research or activities supporting advocacy groups within the previous 6 months or affiliated with or employed by pharmaceutical companies were excluded. AD had a substantial impact on patients' lives. Itch, skin redness, and dry/flaky skin were the most frequently reported symptoms, with > 75% of patients experiencing these symptoms every 1-3 days. Mental health issues were common and resulted in the greatest negative impact on patients' daily lives. Patients perceived clinicians to underestimate the burden of their AD. Patients had little awareness of AD scoring systems and indicated a preference for these to be more clearly incorporated in clinical practice. For an ideal scoring system, patients favored using a combination of patient-reported and clinician-reported outcomes to reflect disease burden and ensure consistency across all settings. This global study generated diverse patient perspectives on the disease burden of AD, their expectations of treatment, and their views on AD scoring methods. These data provide evidence to support the development of patient-centric recommendations for AD management.

Indexed as

Dermatitis, AtopicPatient Reported Outcome MeasuresQualitative ResearchAdolescentAdultAgedCost of IllnessFemaleHumansMaleMiddle AgedQuality of LifeSeverity of Illness IndexYoung AdultAtopic dermatitisPatient-reported outcomesPatient researchQualitative researchQuality of life

Identifiers

PMID38850461
PMCPMC11162389

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.